Last reviewed · How we verify

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin

London School of Hygiene and Tropical Medicine · Phase 3 active Small molecule

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin is a Antimalarial Small molecule drug developed by London School of Hygiene and Tropical Medicine. It is currently in Phase 3 development for Treatment of uncomplicated malaria, Prevention of malaria in areas with high transmission.

Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria.

Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria. Used for Treatment of uncomplicated malaria, Prevention of malaria in areas with high transmission.

At a glance

Generic nameSulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin
SponsorLondon School of Hygiene and Tropical Medicine
Drug classAntimalarial
TargetDihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway
ModalitySmall molecule
Therapeutic areaInfectious Diseases
PhasePhase 3

Mechanism of action

Sulphadoxine and pyrimethamine are a combination of two drugs that work synergistically to treat malaria. Sulphadoxine inhibits the growth of the malaria parasite by interfering with its ability to synthesize folic acid, while pyrimethamine targets the parasite's dihydrofolate reductase enzyme. Amodiaquine is another antimalarial drug that targets the parasite's heme detoxification pathway. Azithromycin, on the other hand, is a broad-spectrum antibiotic that targets a wide range of bacteria by inhibiting protein synthesis.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin

What is Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin is a Antimalarial drug developed by London School of Hygiene and Tropical Medicine, indicated for Treatment of uncomplicated malaria, Prevention of malaria in areas with high transmission.

How does Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin work?

Sulphadoxine acts as a sulfonamide antibacterial agent, inhibiting dihydropteroate synthase, while pyrimethamine inhibits dihydrofolate reductase, and amodiaquine is a 4-aminoquinoline antimalarial that targets the malaria parasite's heme detoxification pathway. Azithromycin is a macrolide antibiotic that inhibits protein synthesis in bacteria.

What is Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin used for?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin is indicated for Treatment of uncomplicated malaria, Prevention of malaria in areas with high transmission.

Who makes Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin is developed by London School of Hygiene and Tropical Medicine (see full London School of Hygiene and Tropical Medicine pipeline at /company/london-school-of-hygiene-and-tropical-medicine).

What drug class is Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin in?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin belongs to the Antimalarial class. See all Antimalarial drugs at /class/antimalarial.

What development phase is Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin in?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin is in Phase 3.

What are the side effects of Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin?

Common side effects of Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin include Nausea, Vomiting, Diarrhea, Abdominal pain, Headache.

What does Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin target?

Sulphadoxine-Pyrimethamine+ Amodiaquine+ Azithromycin targets Dihydropteroate synthase, Dihydrofolate reductase, Heme detoxification pathway and is a Antimalarial.

Related